$150M Private Placement Fuels LB Pharma's Schizophrenia Trial Push
LBRX has more than doubled off its 52-week low of $13.36.
Summary
LB Pharmaceuticals is raising $150 million through a private placement, a significant capital infusion for a company with a $1 billion market cap. The funds arrive as enrollment in the pivotal Phase 3 NOVA-2 trial for schizophrenia drug LB-102 runs ahead of schedule, per the July 22 8-K. This follows the May initiation of the trial and the recent departure of the Chief Medical Officer. The raise extends the cash runway beyond the previously guided Q2 2029, de-risking the path to potential approval. Terms of the placement, including pricing and investor identity, are not yet disclosed.
At the time of this announcement, LBRX was trading at $33.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $13.36 to $38.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.